yte
Open
$98.71
Prev. Close
$98.75
High
$98.71
Low
$98.65
Market Snapshot
$19.72B
13.8
0.23
$4.24B
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Incyte's Q1 2026 results show strong growth, with $1.3 billion in revenue, $1.52 EPS, and $1.4 billion net income, highlighting successful market performance.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Recently from Cashu
Incyte Analyst Opinions Highlight Optimism Amid Industry Challenges and Market Uncertainties
Incyte Faces Divergent Analyst Opinions Amid Evolving Biopharmaceutical Landscape Incyte Corporation stands at a crossroads, with a recent evaluation from 13 analysts revealing a spectrum of opinions…
Incyte Faces Divergent Analyst Opinions Amid Biopharmaceutical Market Dynamics
Incyte: A Study in Contrasting Analyst Perspectives Amidst a Dynamic Biopharmaceutical Landscape Incyte Corporation stands at a pivotal junction within the biopharmaceutical landscape, as recent evalu…
Eli Lilly's Olumiant Shows Promise for Treating Adolescent Alopecia Areata in New Study
### Olumiant's Promising Path for Treating Adolescent Alopecia Areata Eli Lilly and Company is making significant strides in the treatment landscape for severe alopecia areata (AA) in adolescents, fol…
Eli Lilly's Olumiant Advances in Treating Alopecia Areata for Adolescents Following EMA Recommendation
Eli Lilly Advances Alopecia Areata Treatment for Adolescents with Olumiant Eli Lilly and Company announces a pivotal step forward in the treatment of severe alopecia areata (AA) among adolescents, fol…